What is Vivos Therapeutics Inc's earnings per share (EPS)?

Vivos Therapeutics Inc (VVOS) reported diluted earnings per share of $-2.07 for fiscal year 2025. This represents a 6.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Vivos Therapeutics Inc Financials

VVOS

Source SEC Filings (10-K/10-Q) Updated Apr 15, 2026 Currency USD FYE April

This page shows Vivos Therapeutics Inc (VVOS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.72x

For every $1 of reported earnings, Vivos Therapeutics Inc generates $0.72 in operating cash flow (-$15.3M OCF vs -$21.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-14.2x

Vivos Therapeutics Inc earns $-14.2 in operating income for every $1 of interest expense (-$19.9M vs $1.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$6.5M

YoY-56.8%

5Y CAGR-13.1%

Vivos Therapeutics Inc generated $6.5M in revenue in fiscal year 2025. This represents a decrease of 56.8% from the prior year.

EBITDA

-$18.6M

YoY-75.5%

Vivos Therapeutics Inc's EBITDA was -$18.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 75.5% from the prior year.

Net Income

-$21.2M

YoY-90.1%

Vivos Therapeutics Inc reported -$21.2M in net income in fiscal year 2025. This represents a decrease of 90.1% from the prior year.

EPS (Diluted)

$-2.07

YoY+6.8%

Vivos Therapeutics Inc earned $-2.07 per diluted share (EPS) in fiscal year 2025. This represents an increase of 6.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$17.6M

YoY-32.8%

Vivos Therapeutics Inc generated -$17.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 32.8% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

13M

YoY+129.0%

Vivos Therapeutics Inc had 13M shares outstanding in fiscal year 2025. This represents an increase of 129.0% from the prior year.

Margins & Returns

Gross Margin

-6.4%

YoY-66.4pp

5Y CAGR-86.1pp

Vivos Therapeutics Inc's gross margin was -6.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 66.4 percentage points from the prior year.

Operating Margin

-306.7%

YoY-232.4pp

5Y CAGR-214.5pp

Vivos Therapeutics Inc's operating margin was -306.7% in fiscal year 2025, reflecting core business profitability. This is down 232.4 percentage points from the prior year.

Net Margin

-326.3%

YoY-252.3pp

5Y CAGR-234.1pp

Vivos Therapeutics Inc's net profit margin was -326.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 252.3 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$100K

YoY+0.0%

Vivos Therapeutics Inc invested $100K in research and development in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$2.3M

YoY+312.1%

5Y CAGR+81.2%

Vivos Therapeutics Inc invested $2.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 312.1% from the prior year.

VVOS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$6.5M-56.8%	$15.0M+8.9%	$13.8M-13.9%	$16.0M-5.1%	$16.9M+29.2%	$13.1M
Cost of Revenue	$6.9M+14.8%	$6.0M+2906.0%	$200K0.0%	$200K-50.0%	$400K+300.0%	$100K
Gross Profit	-$414K-104.6%	$9.0M+9.0%	$8.3M-17.4%	$10.0M-20.5%	$12.6M+21.0%	$10.4M
R&D Expenses	$100K0.0%	$100K0.0%	$100K-50.0%	$200K0.0%	$200K	N/A
SG&A Expenses	$27.7M+55.1%	$17.9M-20.5%	$22.5M-22.6%	$29.0M+12.6%	$25.8M+60.3%	$16.1M
Operating Income	-$19.9M-78.1%	-$11.2M+35.4%	-$17.3M+30.9%	-$25.0M-22.8%	-$20.4M-69.3%	-$12.0M
Interest Expense	$1.4M	N/A	N/A	N/A	$14K-85.4%	$96K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$21.2M-90.1%	-$11.1M+18.0%	-$13.6M+43.0%	-$23.8M-17.5%	-$20.3M-68.3%	-$12.1M
EPS (Diluted)	$-2.07+6.8%	$-2.22	$-11.14	$-25.90	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$6.8M+77.6%	$3.8M+26.7%	$3.0M-18.4%	$3.7M-4.2%	$3.9M-4.8%	$4.1M+18.6%	$3.4M+5.3%	$3.2M
Cost of Revenue	$2.8M+66.4%	$1.7M+13.5%	$1.5M-49.5%	$3.0M+95.5%	$1.5M+8.8%	$1.4M+1303.0%	$100K+200.0%	-$100K
Gross Profit	$3.9M+86.6%	$2.1M+39.8%	$1.5M-28.0%	$2.1M-10.2%	$2.3M-12.0%	$2.7M+36.9%	$1.9M-7.3%	$2.1M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	$100K+150.0%	-$200K
SG&A Expenses	$7.9M+23.0%	$6.4M+31.0%	$4.9M+12.5%	$4.3M-3.1%	$4.5M+8.9%	$4.1M-16.2%	$4.9M-10.0%	$5.5M
Operating Income	-$4.7M+2.7%	-$4.9M-24.2%	-$3.9M-39.7%	-$2.8M-6.0%	-$2.6M-36.6%	-$1.9M+48.9%	-$3.8M+8.4%	-$4.1M
Interest Expense	$500K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.4M-7.7%	-$5.0M-29.7%	-$3.9M-36.7%	-$2.8M-8.1%	-$2.6M-35.5%	-$1.9M+48.7%	-$3.8M+11.6%	-$4.3M
EPS (Diluted)	$-0.49+10.9%	$-0.55-22.2%	$-0.45	N/A	$-0.40+33.3%	$-0.60+63.2%	$-1.63	N/A

VVOS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$15.3M+42.4%	$10.7M-21.8%	$13.7M-59.3%	$33.7M+33.0%	$25.3M
Current Assets	N/A	$7.5M+203.7%	$2.5M-54.6%	$5.4M-80.1%	$27.3M+34.0%	$20.4M
Cash & Equivalents	N/A	$6.3M+281.0%	$1.6M-53.3%	$3.5M-85.4%	$24.0M+32.0%	$18.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$430K+112.9%	$202K-55.8%	$457K-62.0%	$1.2M-15.9%	$1.4M
Goodwill	N/A	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M+6.4%	$2.7M
Total Liabilities	N/A	$7.3M-29.0%	$10.3M+15.7%	$8.9M+9.4%	$8.2M-3.1%	$8.4M
Current Liabilities	N/A	$5.0M-31.7%	$7.3M+7.0%	$6.8M-9.3%	$7.5M-4.2%	$7.8M
Long-Term Debt	N/A	$1.2M0.0%	$1.2M	N/A	$1.3M+199.1%	$423K
Total Equity	N/A	$8.0M+1835.3%	$411K-91.4%	$4.8M-81.2%	$25.5M+51.0%	$16.9M
Retained Earnings	N/A	-$104.2M-12.0%	-$93.1M-17.1%	-$79.5M-42.9%	-$55.6M-57.4%	-$35.3M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$25.6M-1.5%	$26.0M+130.7%	$11.3M-26.2%	$15.3M-0.4%	$15.3M-3.1%	$15.8M+34.2%	$11.8M+10.0%	$10.7M
Current Assets	$5.8M-14.0%	$6.7M+86.6%	$3.6M-51.7%	$7.5M+1.0%	$7.4M-5.8%	$7.9M+117.4%	$3.6M+46.7%	$2.5M
Cash & Equivalents	$3.1M-29.9%	$4.4M+88.0%	$2.3M-62.6%	$6.3M-0.8%	$6.3M-8.6%	$6.9M+164.4%	$2.6M+58.9%	$1.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$2.1M+30.7%	$1.6M+127.4%	$718K+67.0%	$430K-5.3%	$454K+14.9%	$395K-24.8%	$525K+159.9%	$202K
Goodwill	$8.4M0.0%	$8.4M+197.2%	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M0.0%	$2.8M
Total Liabilities	$23.1M+7.7%	$21.4M+212.0%	$6.9M-6.2%	$7.3M-4.6%	$7.7M-19.1%	$9.5M-15.4%	$11.2M+8.8%	$10.3M
Current Liabilities	$7.4M+15.7%	$6.4M+36.7%	$4.7M-5.6%	$5.0M-2.9%	$5.1M-22.8%	$6.6M-17.7%	$8.1M+10.7%	$7.3M
Long-Term Debt	$8.4M+8.0%	$7.8M	N/A	$1.2M0.0%	$1.2M0.0%	$1.2M	N/A	$1.2M
Total Equity	$2.5M-44.8%	$4.6M+4.0%	$4.4M-44.6%	$8.0M+3.8%	$7.7M+20.8%	$6.3M+990.5%	$582K+41.6%	$411K
Retained Earnings	-$118.5M-4.8%	-$113.1M-4.6%	-$108.1M-3.7%	-$104.2M-2.8%	-$101.4M-2.6%	-$98.7M-2.0%	-$96.8M-4.0%	-$93.1M

VVOS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$15.3M-20.3%	-$12.7M-6.2%	-$11.9M+39.0%	-$19.6M-24.5%	-$15.7M-177.0%	-$5.7M
Capital Expenditures	$2.3M+312.1%	$568K-29.3%	$803K-13.1%	$924K-61.4%	$2.4M+1896.7%	$120K
Free Cash Flow	-$17.6M-32.8%	-$13.3M-4.0%	-$12.7M+37.8%	-$20.5M-13.1%	-$18.1M-212.6%	-$5.8M
Investing Cash Flow	-$7.5M-1225.0%	-$568K+33.4%	-$853K+7.7%	-$924K+64.6%	-$2.6M-2073.3%	-$120K
Financing Cash Flow	$18.6M+3.8%	$17.9M+63.7%	$10.9M	N/A	$24.2M+2.7%	$23.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$4.2M-19.1%	-$3.5M+8.0%	-$3.8M-29.1%	-$2.9M+29.8%	-$4.2M-37.4%	-$3.0M-21.1%	-$2.5M+8.4%	-$2.7M
Capital Expenditures	-$83K-110.8%	$771K+532.0%	$122K-26.1%	$165K-14.1%	$192K+220.0%	$60K-60.3%	$151K-8.5%	$165K
Free Cash Flow	-$4.2M+0.5%	-$4.3M-8.9%	-$3.9M-26.2%	-$3.1M+29.1%	-$4.4M-40.9%	-$3.1M-16.5%	-$2.7M+8.4%	-$2.9M
Investing Cash Flow	$83K+101.4%	-$5.9M-4741.0%	-$122K+26.1%	-$165K+14.1%	-$192K-220.0%	-$60K+60.3%	-$151K+8.5%	-$165K
Financing Cash Flow	$2.8M	N/A	N/A	$3.1M-19.4%	$3.8M-48.8%	$7.4M+103.6%	$3.6M+1.9%	$3.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VVOS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	-6.4%-66.4pp	60.0%+0.1pp	59.9%-2.6pp	62.5%-12.1pp	74.7%-5.0pp	79.7%
Operating Margin	-306.7%-232.4pp	-74.3%+51.0pp	-125.3%+30.9pp	-156.2%-35.5pp	-120.7%-28.6pp	-92.2%
Net Margin	-326.3%-252.3pp	-74.1%+24.3pp	-98.4%+50.4pp	-148.8%-28.7pp	-120.2%-27.9pp	-92.3%
Return on Equity	N/A	-140.0%+3164.9pp	-3304.9%-2808.2pp	-496.7%-417.2pp	-79.4%-8.2pp	-71.3%
Return on Assets	N/A	-72.9%+53.7pp	-126.6%+47.2pp	-173.8%-113.6pp	-60.2%-12.6pp	-47.6%
Current Ratio	N/A	1.50+1.2	0.34-0.5	0.80-2.8	3.64+1.0	2.60
Debt-to-Equity	N/A	0.15-2.8	2.92+1.1	1.86+1.8	0.05+0.0	0.03
FCF Margin	-271.4%-183.2pp	-88.2%+4.2pp	-92.4%+35.6pp	-128.0%-20.6pp	-107.4%-63.0pp	-44.4%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	58.0%+2.8pp	55.2%+5.2pp	50.0%-6.7pp	56.7%-3.8pp	60.5%-4.9pp	65.4%+8.7pp	56.6%-7.7pp	64.3%
Operating Margin	-69.8%+57.6pp	-127.4%+2.5pp	-129.9%-54.1pp	-75.8%-7.3pp	-68.5%-20.8pp	-47.8%+62.9pp	-110.7%+16.6pp	-127.3%
Net Margin	-79.6%+51.6pp	-131.2%-3.1pp	-128.1%-51.7pp	-76.4%-8.7pp	-67.8%-20.2pp	-47.6%+62.5pp	-110.1%+21.1pp	-131.1%
Return on Equity	-213.3%-103.9pp	-109.4%-21.7pp	-87.7%-52.1pp	-35.5%-1.4pp	-34.1%-3.7pp	-30.4%+616.1pp	-646.6%+389.7pp	-1036.3%
Return on Assets	-21.1%-1.8pp	-19.3%+15.0pp	-34.3%-15.8pp	-18.5%-1.4pp	-17.1%-4.9pp	-12.2%+19.7pp	-31.9%+7.8pp	-39.7%
Current Ratio	0.78-0.3	1.05+0.3	0.77-0.7	1.50+0.1	1.44+0.3	1.18+0.7	0.45+0.1	0.34
Debt-to-Equity	3.31+1.6	1.69+0.1	1.56+1.4	0.150.0	0.16-0.0	0.19-19.1	19.28+16.4	2.92
FCF Margin	-62.6%+49.1pp	-111.7%+18.3pp	-129.9%-45.9pp	-84.0%+29.5pp	-113.5%-36.8pp	-76.7%+1.3pp	-78.0%+11.7pp	-89.7%

Similar Companies

$31.8M

$40.3M

$55.4M

$30.8M

$18.0M

Frequently Asked Questions

What is Vivos Therapeutics Inc's annual revenue?

Vivos Therapeutics Inc (VVOS) reported $6.5M in total revenue for fiscal year 2025. This represents a -56.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Vivos Therapeutics Inc's revenue growing?

Vivos Therapeutics Inc (VVOS) revenue declined by 56.8% year-over-year, from $15.0M to $6.5M in fiscal year 2025.

Is Vivos Therapeutics Inc profitable?

No, Vivos Therapeutics Inc (VVOS) reported a net income of -$21.2M in fiscal year 2025, with a net profit margin of -326.3%.

What is Vivos Therapeutics Inc's EBITDA?

Vivos Therapeutics Inc (VVOS) had EBITDA of -$18.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Vivos Therapeutics Inc's gross margin?

Vivos Therapeutics Inc (VVOS) had a gross margin of -6.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Vivos Therapeutics Inc's operating margin?

Vivos Therapeutics Inc (VVOS) had an operating margin of -306.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Vivos Therapeutics Inc's net profit margin?

Vivos Therapeutics Inc (VVOS) had a net profit margin of -326.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Vivos Therapeutics Inc's free cash flow?

Vivos Therapeutics Inc (VVOS) generated -$17.6M in free cash flow during fiscal year 2025. This represents a -32.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Vivos Therapeutics Inc's operating cash flow?

Vivos Therapeutics Inc (VVOS) generated -$15.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Vivos Therapeutics Inc's capital expenditures?

Vivos Therapeutics Inc (VVOS) invested $2.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Vivos Therapeutics Inc spend on research and development?

Vivos Therapeutics Inc (VVOS) invested $100K in research and development during fiscal year 2025.

How many shares does Vivos Therapeutics Inc have outstanding?

Vivos Therapeutics Inc (VVOS) had 13M shares outstanding as of fiscal year 2025.

Are Vivos Therapeutics Inc's earnings high quality?

Vivos Therapeutics Inc (VVOS) has an earnings quality ratio of 0.72x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Vivos Therapeutics Inc cover its interest payments?

Vivos Therapeutics Inc (VVOS) has an interest coverage ratio of -14.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.